Celleron, Nuance Biotech deal

Celleron granted Nuance an exclusive option to develop and commercialize CXD101 and CXD201 in South Africa, Taiwan and China, including Macau and Hong Kong. CXD101 is a histone deacetylase (HDAC) inhibitor, and CDX201 is oral topoisomerase I (TOP1) inhibitor. Both compounds are in Phase I development. ...